Notable Labs, Ltd. (NTBL)
- Previous Close
0.3901 - Open
0.3800 - Bid --
- Ask --
- Day's Range
0.4000 - 0.4000 - 52 Week Range
0.3800 - 5.2700 - Volume
17,032 - Avg. Volume
77,678 - Market Cap (intraday)
3.864M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0900 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.00
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California. On October 13, 2024, Notable Labs, Ltd. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
www.notablelabs.comRecent News: NTBL
View MorePerformance Overview: NTBL
Trailing total returns as of 10/14/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NTBL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NTBL
View MoreValuation Measures
Market Cap
3.86M
Enterprise Value
1.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.34
Price/Book (mrq)
0.54
Enterprise Value/Revenue
5.01
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-106.09%
Return on Equity (ttm)
--
Revenue (ttm)
313k
Net Income Avi to Common (ttm)
-10.54M
Diluted EPS (ttm)
-1.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
4.09M
Total Debt/Equity (mrq)
24.98%
Levered Free Cash Flow (ttm)
-11.46M
Research Analysis: NTBL
View MoreCompany Insights: NTBL
NTBL does not have Company Insights